Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Behavioral Health topic
No spam. Unsubscribe anytime.
Committee hears expansive psilocybin licensing proposal; DHHS flags start‑up costs
Summary
Representative Mike Moffat proposed a comprehensive regulatory framework for medical psilocybin (HB1796) that would create a licensing board and treatment standards; DHHS estimated start‑up costs between $1.25 million and $4 million and said current staff cannot absorb program implementation without new appropriations.
Representative Mike Moffat presented HB1796, a detailed bill that would create a regulated framework for medical psilocybin services including a psilocybin licensing board, licensing for cultivators, testing labs and therapy providers, and clinical standards for treatment delivery.
Sponsor intent and structure
Moffat said his interest stems from veterans and others with treatment‑resistant conditions and that he used language from other states to craft a comprehensive bill. He described psilocybin as a “non‑addictive psychedelic” and proposed a six‑member licensing board and extensive guardrails for clinical practice and licensing.
DHHS fiscal concerns and expert caution
Jenny O’Higgins, DHHS legislative liaison for behavioral health, told the committee the department is not taking a formal position but must note significant start‑up and ongoing costs. The department submitted fiscal detail to the LBA and indicated a preliminary fiscal range of about $1,250,000 to $4,000,000 to establish regulatory infrastructure, IT systems, training and oversight staff. She said DHHS currently lacks required expertise and could not absorb those costs without appropriation.
Public witnesses and expert views
Supporters and opponents addressed potential benefits for PTSD and treatment‑resistant depression, and raised concerns about evidence quality, commercialization risks and whether research meets Phase‑3 clinical trial standards. Some witnesses urged careful federal regulatory alignment and rigorous clinical studies before establishing statewide clinical access. Others—including veterans and clinicians—emphasized anecdotal and developing research supporting therapeutic potential.
What’s next: The committee requested a pending fiscal note and additional implementation detail; members discussed whether a lighter advisory approach or a phased pilot might be a prudent path forward.
Sources: Representative Mike Moffat (prime sponsor), Jenny O'Higgins (DHHS), Senator Henry Giesen, various advocates and opponents.
